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Introduction 
Nanoparticle or nanotechnology-based drug administration 
is analyzed by researchers for the potential opportunities 
and benefits they offer in drug delivery1-3. Nanoparticle 
guided drug delivery can cross the blood-brain barrier. Drug 
delivery across the blood-brain barrier was a challenging 
factor before. Drugs either delivered continuously over time 
ends up accumulating in the patient resulting in toxicity 
effects, like cytotoxicity in the case of a chemotherapeutic 
agent4-10. In other situations, the challenge of the blood-brain 
barrier could result in lowered efficacy of treatment.  
In the treatment of psychosis, physicians lack precise 
knowledge of how the underlying mechanism of psychosis is 
caused or triggered. In this very fragile stage, very proper 
and controlled delivery of antipsychotics is believed to 
improve the psychotic state of the patient. This adequate and 
controlled delivery is possible with the use of nanoparticles, 
the size of 1-500 nm. At this size, they are capable of 
crossing the biological barriers like the blood-brain barrier. 
Sun et al.11 identified in their research on antipsychotics that 
nanoparticle constructed from different polymers, 
dendrimers, solid-lipids, peptides and more can cross not 
only the blood-brain barrier but also offer provisions for 
more efficient release of the drug12-15. In the case of 
antipsychotic medication delivery, Sun et al.7 identified that 
the hydrophobicity of antipsychotics had a negative effect. 
The antipsychotics by themselves pass through the BBB, but 
then they move too soon. The patients to whom the drug has 
been administered are not able to absorb the drugs and 
hence do not get relief from their condition16-21. In this 
context, nanoparticle drug delivery facilitates a more 
controlled release. In particular, the use of nanoparticle 
technology will release in slow release of the drugs. The 
nanoparticles encapsulate the drugs and enable this sluggish 
release behavior. 
Kang et al.8,22 argue that this very size and characteristics of 
the nanoparticle that renders it the capability to cross the 
blood-brain barrier is what makes it an ideal candidate for 
drug delivery in the case of malignant brain tumors. In 
malignant brain tumors like that of glioblastoma, the 
debulking surgery has to be followed up with targeted drug 
delivery22-25. Most chemotherapeutic drugs cannot cross the 
blood-brain barrier and end up accumulating, resulting in 
cytotoxicity. Nanoparticles offer high potential for targeted 
drug delivery. This is attributed to its capability to cross the 
blood-brain barrier. Sun et al. also show how the drugs will 
also be able to pass through complex tumor 
microvasculature, and this also holds many treatment 
benefits for psychosis conditions that are triggered because 
of the growth of a tumor11,26,27. 
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Figure 1: Capillary structure, the general capillary structure and the capillary structure of the brain is presented here. Different 
transportation mechanisms can be observed in the brand capillary and the general capillary8. 
 
Sun et al.4 also argued that this feature of nanoparticles 
could also help reduce multidrug resistance. The research 
work was carried out to analyze two co-delivery aspects. 
The first was co-delivery of chemotherapeutics with MDR 
inhibitors, and the second was co-delivery of 
chemotherapeutics with sensitizers28-31. When therapeutic 
nanoparticles containing a combination of cytotoxic drugs 
are used with efflux pumps inhibitors, there is better 
potential to suppress MDR. Similarly, MDR alterations 
caused by the apoptosis pathways are handled better when 
sensitizer compounds are used with nanoparticle drug 
delivery method. Both these methods of co-delivery with re-
sensitizations by either MDR inhibitor or by modulation of 
siRNA are observed to be effective32-36. As Sun et al.33 
identified, an enhanced permeability effect is observed when 
nanoparticles are used for drug delivery. The leakier nature 
of the tumor vasculature has led to the drug being dispersed 
outside the cells affecting cells other than the tumor cells. 
However, nanotechnology allows for higher intercellular 
toxicity that is effective against cancer cells.  
The review sought to understand how nanoparticles are 
improving the efficiency of drug administration across the 
blood-brain barrier. Researchers identified the use of 
nanotechnology-based drug administration as being efficient 
for drug delivery across the blood-brain barrier. Firstly, in 
complex tumor vasculatures, drug delivery is affected. 
Secondly, when drug targeting tumors cross the blood-brain 
barrier effectively, they will have a better chance of being 
retained within the cells thus effectively targeting cancer. 
Thirdly, this would reduce the cytotoxicity and associated 
MDR effects of chemotherapeutic drug deliveries. Finally, in 
the case of antipsychotics, it is also possible to cause a slow 
release of a drug.  
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